Anocca was founded in 2014 to build biotechnologies, processes and infrastructure needed to decode T-cell immunity, with the ambition to build new forms of T-cell immunotherapies. During the past decade we've invented, refined and deployed technologies and infrastructure into a deep tech platform to analyse T-cell biology at scale. Today we focus on the development and manufacturing of libraries of TCR-T cell therapies for the hardest to treat cancers.
We are more than 120 scientists, software developers, engineers, manufacturing and quality specialist, and dedicated support and business personnel working out of state-of-the-art facilities in Sweden.
We’ve assembled a talented multidisciplinary team from all over the globe. Hailing from over 35 different nations, we bring together the diverse talent and perspectives needed to create our unique platform company and to deliver on our vision to decode T-cell immunity and engineer powerful T-cell immunotherapies.
